Adjuvant chemoradiation in resected gallbladder cancer: a prognostic index model for predicting overall survival

被引:1
|
作者
Sole, Claudio V. [1 ,2 ,3 ,4 ]
Vargas, Lorena [1 ,2 ,3 ]
Sole, Vicente J. [5 ]
Larsen, Francisco [1 ,2 ,3 ]
Sole, Sebastian [1 ,2 ,3 ]
机构
[1] Inst Radiomed, Dept Radiat Oncol, Ave Amer Vespucio Norte 1314, Santiago 7630370, Chile
[2] Inst Radiomed, Radiat Med Program, Santiago, Chile
[3] Diego Portales Univ, Sch Med, Santiago, Chile
[4] Inst Invest Sanitaria Gregorio Maranon, Madrid, Spain
[5] San Sebastian Univ, Sch Med, Santiago, Chile
关键词
Gallbladder cancer; Radiotherapy; Overall survival; BEAM RADIATION-THERAPY; CONCURRENT CHEMOTHERAPY; CHEMORADIOTHERAPY; RADIOTHERAPY; CARCINOMA;
D O I
10.1007/s13566-019-00382-2
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
PurposePatients with gallbladder cancer (GBC) have a dismal prognosis. We investigated outcomes and risk factors for overall survival (OS) in patients treated with radical surgery and adjuvant chemoradiotherapy (CRT).Materials/methodsA total of 212 patients with LAGC (pT3 59% and/or pN+ 52%) were studied. The primary endpoint of the analysis was OS. We constructed a risk scoring system in which points were assigned to each risk factor by dividing each beta coefficient in the final model by the lowest beta coefficient and rounding to the nearest integer. A risk score was assigned to each subject by adding up the points for each risk factor present. Subjects were then divided into three risk groups based on their risk scores (0 points=low risk, 1-2 points=intermediate risk, 3-6 points=high risk).ResultsMedian follow-up was 46.2months (2-235). Five-year OS for the entire cohort was 53%. In multivariate analysis, higher pT stage [HR, 2.43 (1.29-3.68); p=0.01], R1 resection [HR, 5.06 (3.12-8.19); p<0.001], and number of surgical procedures [HR, 1.41 (1.01-2.16); p=0.05] were associated with an increased risk of death. Five-year OS for patients with low (n=63), intermediate (n=94), and high (n=55) risk was 79.1%, 51.2%, and 9.5%, respectively.ConclusionOverall results after multimodality treatment of GBC are promising. A risk model was generated to determine a prognostic index for individual patients with GBC. Classification of risk factors for death has contributed to propose a prognostic index that could allow us to guide risk-adapted tailored treatment.
引用
收藏
页码:157 / 162
页数:6
相关论文
共 50 条
  • [21] Prognostic model for predicting overall survival in children and adolescents with rhabdomyosarcoma
    Yang, Limin
    Takimoto, Tetsuya
    Fujimoto, Junichiro
    [J]. BMC CANCER, 2014, 14
  • [22] Prognostic significance of survivin in resected gallbladder cancer
    Nigam, Jaya
    Chandra, Abhijit
    Kazmi, Hasan Raza
    Parmar, Devendra
    Singh, Devendra
    Gupta, Vishal
    [J]. JOURNAL OF SURGICAL RESEARCH, 2015, 194 (01) : 57 - 62
  • [23] Prognostic model for predicting overall survival in children and adolescents with rhabdomyosarcoma
    Limin Yang
    Tetsuya Takimoto
    Junichiro Fujimoto
    [J]. BMC Cancer, 14
  • [24] Immediate versus delayed adjuvant chemoradiation for resected pancreatic cancer: An analysis of local control and survival
    Childs, Stephanie Krejcarek
    Mamon, Harvey J.
    Wo, Jennifer Yon-Li
    Blaszkowsky, Lawrence Scott
    Fernandez-del Castillo, Carlos
    Swanson, Richard
    Wolpin, Brian M.
    Kwak, Eunice Lee
    Allen, Jill N.
    Zhu, Andrew X.
    Clark, Jeffrey W.
    Wadlow, Raymond Couric
    Ryan, David P.
    Hong, Theodore S.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (04)
  • [25] Gemcitabine and Taxane Adjuvant Therapy with Chemoradiation in Resected Pancreatic Cancer: A Novel Strategy for Improved Survival?
    Zaheer S. Kanji
    Alicia M. Edwards
    Margaret T. Mandelson
    Nadav Sahar
    Bruce S. Lin
    Kasra Badiozamani
    Guobin Song
    Adnan Alseidi
    Thomas R. Biehl
    Richard A. Kozarek
    William S. Helton
    Vincent J. Picozzi
    Flavio G. Rocha
    [J]. Annals of Surgical Oncology, 2018, 25 : 1052 - 1060
  • [26] Gemcitabine and Taxane Adjuvant Therapy with Chemoradiation in Resected Pancreatic Cancer: A Novel Strategy for Improved Survival?
    Kanji, Zaheer S.
    Edwards, Alicia M.
    Mandelson, Margaret T.
    Sahar, Nadav
    Lin, Bruce S.
    Badiozamani, Kasra
    Song, Guobin
    Alseidi, Adnan
    Biehl, Thomas R.
    Kozarek, Richard A.
    Helton, William S.
    Picozzi, Vincent J.
    Rocha, Flavio G.
    [J]. ANNALS OF SURGICAL ONCOLOGY, 2018, 25 (04) : 1052 - 1060
  • [27] Prognostic factors affecting overall survival in gallbladder cancer on cisplatin-gemcitabine
    Agrawal, Sushma
    Saxena, Rajan
    [J]. ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2018, 14 : 92 - 92
  • [28] Limited Use of Adjuvant Therapy in Patients With Resected Gallbladder Cancer Despite a Strong Association With Survival
    Mitin, Timur
    Enestvedt, C. Kristian
    Jemal, Ahmedin
    Sineshaw, Helmneh M.
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2017, 109 (07)
  • [29] TOLERABILITY OF CHEMORADIATION THERAPY IN THE ADJUVANT TREATMENT OF RESECTED GASTRIC CANCER
    Ferreira, Ana Flavia
    Mariano, Monica
    Pinto, Ana Catarina
    Fardilha, Carlos
    Bonito, Nuno
    Jacinto, Paula
    Ribeiro, Joao
    Alves, Paula
    Pereira, Moura
    Gervasio, Helena
    [J]. ANNALS OF ONCOLOGY, 2011, 22 : v53 - v53
  • [30] Adjuvant chemoradiation for resected gastric cancer: Our preliminary experience
    Sarcina, I.
    Romiti, A.
    Ferri, M.
    Osti, M.
    Mercantini, P.
    Durante, V.
    Di Rocco, R.
    Berardi, F.
    D'Antonio, C.
    Enrici, R. Maurizi
    Marchetti, P.
    [J]. ANNALS OF ONCOLOGY, 2007, 18 : 14 - 14